Mandatory implementation of bioequivalence test in drug license eyed

Published: 2002-06-12 06:59:00

Updated: 2002-06-12 06:59:00

The Korea Food and Drug Administration (KFDA) says it will draft a series of drug-related measures relating to more expanded implementation of bioequivalence test during drug license and re-evaluation on drug necessitating the bioequivalence test until June 12. The KDFA further notes:

- During...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK